Protective Effects of Therapeutic Neutrophil Depletion and Myeloperoxidase Inhibition on Left Ventricular Function and Remodeling in Myocardial Infarction
Henning Guthoff,Alexander Hof,Anna Klinke,Martina Maaß,Jürgen Konradi,Dennis Mehrkens,Simon Geißen,Felix S. Nettersheim,Simon Braumann,Erik Michaelsson,Richard J. Nies,Samuel Lee,Marie-Christin Redzinski,Vera B. M. Peters,Harshal N. Nemade,Philipp von Stein,Holger Winkels,Volker Rudolph,Stephan Baldus,Matti Adam,Martin Mollenhauer
DOI: https://doi.org/10.3390/antiox12010033
IF: 7.675
2022-12-25
Antioxidants
Abstract:Myocardial infarction (MI) is a leading cause of morbidity and mortality worldwide. Improved survival has led to an increasing incidence of ischemic cardiomyopathy, making it a major reason for hospitalization in the western world. The inflammatory response in the ischemic myocardium determines the extent of structural remodeling and functional deterioration, with neutrophils (PMN) being a key modulator of the propagation and resolution of inflammation. The heme enzyme myeloperoxidase (MPO) is abundantly expressed in PMN and is an important mediator of their inflammatory capacities. Here, we examine the effects of PMN reduction, MPO deficiency and MPO inhibition in two murine models of MI. Reduction in PMN count resulted in less scar formation and improved cardiac function. Similar results were obtained in genetically MPO deficient mice, suggesting that MPO is a critical factor in PMN-mediated cardiac remodeling. To test our findings in a therapeutic approach, we orally administered the MPO inhibitor AZM198 in the context of MI and could demonstrate improved cardiac function and reduced structural remodeling. Therefore, MPO appears to be a favorable pharmacological target for the prevention of long-term morbidity after MI.
biochemistry & molecular biology,chemistry, medicinal,food science & technology